Extracellular Vesicles as Carriers of Suicide mRNA and/or Protein in Cancer Therapy
Authors:
- 12 December 2018
- book chapter
- Published by Springer Nature
- Vol. 1895, 87-96
Abstract
Gene therapy involves the introduction of genes (termed transgenes) into cells to compensate for a deficiency or to make a beneficial protein. Gene therapy can used as a form of cancer treatment. A particularly attractive paradigm in this regard involves the selective introduction of transgenes into cancer cells that converts inactive prodrugs into active chemotherapeutic agents, thereby triggering the death of cancer cells. Since prodrugs are inactive, they tend not to cause significant side-effects and are well-tolerated by patients relative to conventional chemotherapy. Several viral and nonviral vectors have been used as delivery tools for suicide gene therapy. Extracellular vesicles (EVs) are now recognized as a promising class of nonviral delivery vectors. Here, we describe a method in which a suicide fusion gene construct is loaded into EVs derived from a non-tumorigenic cell line. Delivery of these modified EVs to glioblastoma cell lines and spheroids decreases glioblastoma cell viability, induces apoptotic cell death, and inhibits tumor growth in vivo.Keywords
This publication has 17 references indexed in Scilit:
- Extracellular vesicle-mediated suicide mRNA/protein delivery inhibits glioblastoma tumor growth in vivoCancer Gene Therapy, 2016
- Through the wall: extracellular vesicles in Gram-positive bacteria, mycobacteria and fungiNature Reviews Microbiology, 2015
- Therapeutic Applications of Extracellular Vesicles: Clinical Promise and Open QuestionsAnnual Review of Pharmacology and Toxicology, 2015
- Genetically Engineered Microvesicles Carrying Suicide mRNA/Protein Inhibit Schwannoma Tumor GrowthMolecular Therapy, 2013
- Exosome-mediated delivery of siRNA in vitro and in vivoNature Protocols, 2012
- Sensitivity of 5-fluorouracil-resistant cancer cells to adenovirus suicide gene therapyCancer Gene Therapy, 2006
- Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicityCancer Gene Therapy, 2005
- Concomitant expression ofE. colicytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosineFEMS Microbiology Letters, 1998
- In Vivo Adenovirus-Mediated Gene Transfer of the Escherichia coli Cytosine Deaminase Gene to Human Colon Carcinoma-Derived Tumors Induces Chemosensitivity to 5-FluorocytosineHuman Gene Therapy, 1995
- Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system.Proceedings of the National Academy of Sciences, 1992